Eptacog Beta Lowers Surgery Risk for Hem A Patients With Inhibitors

Eptacog Beta Lowers Surgery Risk for Hem A Patients With Inhibitors

309669

Eptacog Beta Lowers Surgery Risk for Hem A Patients With Inhibitors

Eptacog beta was safe and 100% effective at preventing bleeds during and after minor surgeries in hemophilia A patients with inhibitors, according to data from a Phase 3 trial. The treatment’s efficacy at managing bleeds dropped with major surgeries, with post-operative success seen in 66.7% of evaluated cases. Overall, these findings support the potential of eptacog beta in helping to manage bleeds during and after surgery in hemophilia patients with inhibitors. Trial results were reported in…

You must be logged in to read/download the full post.